Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03319628
Title First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mersana Therapeutics
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.